Disease-toxicant screen reveals a neuroprotective interaction between Huntington's disease and manganese exposure

Journal of Neurochemistry

Volumn 112, Issue 1, 2010, Pages 227-237

  Williams, B Blairanne ^a,b   Li, Daphne ^b   Wegrzynowicz, Michal ^b   Vadodaria, Bhavin K ^b   Anderson, Joel G ^c   Kwakye, Gunnar F ^a,b   Aschner, Michael ^a,b   Erikson, Keith M ^c   Bowman, Aaron B ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF NORTH CAROLINA AT GREENSBORO   (United States)

Author keywords

Gene environment Interactions; Huntington's disease; Manganese; Neurodegeneration; Neuroprotection; Neurotoxicity

Indexed keywords

ACTIN; CADMIUM; COBALT; COPPER; HUNTINGTIN; IRON; LEAD; MANGANESE; NICKEL; PROTEIN KINASE B; ZINC;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CELL LEVEL; CELL MUTANT; CELL STRESS; CONTROLLED STUDY; CORPUS STRIATUM; EXPOSURE; GENE; GENOTYPE ENVIRONMENT INTERACTION; HUNTINGTIN GENE; HUNTINGTON CHOREA; MOUSE; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WILD TYPE;

ANIMALS; CATTLE; CELL LINE; CELL SURVIVAL; DRUG EVALUATION, PRECLINICAL; HUMANS; HUNTINGTON DISEASE; MANGANESE; MICE; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS;

MUS;

EID: 71649110532     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2009.06445.x     Document Type: Article

References (42)

1. Anderson J. G., Fordahl S. C., Cooney P. T., Weaver T. L., Colyer C. L. Erikson K. M. (2009) Extracellular norepinephrine, norepinephrine receptor and transporter protein and mRNA levels are differentially altered in the developing rat brain due to dietary iron deficiency and manganese exposure. Brain Res. 1281, 1 14.
2. Apostol B. L., Illes K., Pallos J. et al. (2006) Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity. Hum. Mol. Genet. 15, 273 285.
3. Aschner M., Erikson K. M. Dorman D. C. (2005) Manganese dosimetry: species differences and implications for neurotoxicity. Crit. Rev. Toxicol. 35, 1 32.
4. Bae J. H., Jang B. C., Suh S. I., Ha E., Baik H. H., Kim S. S., Lee M. Y. Shin D. H. (2006) Manganese induces inducible nitric oxide synthase (iNOS) expression via activation of both MAP kinase and PI3K/Akt pathways in BV2 microglial cells. Neurosci. Lett. 398, 151 154.
5. Beal M. F., Brouillet E., Jenkins B. G. et al. (1993) Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 13, 4181 4192.
6. Bowman A. B., Lam Y. C., Jafar-Nejad P. et al. (2007) Duplication of Atxn1l suppresses SCA1 neuropathology by decreasing incorporation of polyglutamine-expanded ataxin-1 into native complexes. Nat. Genet. 39, 373 379.
7. Brunet A., Datta S. R. Greenberg M. E. (2001) Transcription-dependent and-independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr. Opin. Neurobiol. 11, 297 305.
8. Bush A. I. (2000) Metals and neuroscience. Curr. Opin. Chem. Biol. 4, 184 191.
9. Cattaneo E. Conti L. (1998) Generation and characterization of embryonic striatal conditionally immortalized ST14A cells. J. Neurosci. Res. 53, 223 234.
10. Chen L., Liu L., Luo Y. Huang S. (2008) MAPK and mTOR pathways are involved in cadmium-induced neuronal apoptosis. J. Neurochem. 105, 251 261.
11. Colin E., Regulier E., Perrin V., Durr A., Brice A., Aebischer P., Deglon N., Humbert S. Saudou F. (2005) Akt is altered in an animal model of Huntington's disease and in patients. Eur. J. Neurosci. 21, 1478 1488.
12. Dexter D. T., Carayon A., Javoy-Agid F., Agid Y., Wells F. R., Daniel S. E., Lees A. J., Jenner P. Marsden C. D. (1991) Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114 (Pt. 4 1953 1975.
13. Dodd C. A., Ward D. L. Klein B. G. (2005) Basal Ganglia accumulation and motor assessment following manganese chloride exposure in the C57BL/6 mouse. Int. J. Toxicol. 24, 389 397.
14. Ehrich M. Sharova L. (2000) In vitro methods for detecting cytotoxcity. Curr. Protoc. Toxicol. 3, 6.2.11 6.2.12.
15. Fox J. H., Kama J. A., Lieberman G. et al. (2007) Mechanisms of copper ion mediated Huntington's disease progression. PLoS ONE 2, e334.
16. Garcia S. J., Gellein K., Syversen T. Aschner M. (2007) Iron deficient and manganese supplemented diets alter metals and transporters in the developing rat brain. Toxicol. Sci. 95, 205 214.
17. Gines S., Ivanova E., Seong I. S., Saura C. A. MacDonald M. E. (2003a) Enhanced Akt signaling is an early pro-survival response that reflects N-methyl-D-aspartate receptor activation in Huntington's disease knock-in striatal cells. J. Biol. Chem. 278, 50514 50522.
18. Gines S., Seong I. S., Fossale E., Ivanova E., Trettel F., Gusella J. F., Wheeler V. C., Persichetti F. MacDonald M. E. (2003b) Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice. Hum. Mol. Genet. 12, 497 508.
19. Hilditch-Maguire P., Trettel F., Passani L. A., Auerbach A., Persichetti F. MacDonald M. E. (2000) Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles. Hum. Mol. Genet. 9, 2789 2797.
20. Humbert S., Bryson E. A., Cordelieres F. P., Connors N. C., Datta S. R., Finkbeiner S., Greenberg M. E. Saudou F. (2002) The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev. Cell 2, 831 837.
21. Imarisio S., Carmichael J., Korolchuk V. et al. (2008) Huntington's disease: from pathology and genetics to potential therapies. Biochem. J. 412, 191 209.
22. Kreutz C., Bartolome Rodriguez M. M., Maiwald T., Seidl M., Blum H. E., Mohr L. Timmer J. (2007) An error model for protein quantification. Bioinformatics 23, 2747 2753.
23. Lee E. S., Yin Z., Milatovic D., Jiang H. Aschner M. (2009) Estrogen and tamoxifen protect against Mn-induced toxicity in rat cortical primary cultures of neurons and astrocytes. Toxicol. Sci. 110, 156 167.
24. Li M., Xia T., Jiang C. S., Li L. J., Fu J. L. Zhou Z. C. (2003) Cadmium directly induced the opening of membrane permeability pore of mitochondria which possibly involved in cadmium-triggered apoptosis. Toxicology 194, 19 33.
25. Liao S. L., Ou Y. C., Chen S. Y., Chiang A. N. Chen C. J. (2007) Induction of cyclooxygenase-2 expression by manganese in cultured astrocytes. Neurochem. Int. 50, 905 915.
26. Lopez E., Arce C., Oset-Gasque M. J., Canadas S. Gonzalez M. P. (2006) Cadmium induces reactive oxygen species generation and lipid peroxidation in cortical neurons in culture. Free Radic. Biol. Med. 40, 940 951.
27. Mao Z., Choo Y. S. Lesort M. (2006) Cystamine and cysteamine prevent 3-NP-induced mitochondrial depolarization of Huntington's disease knock-in striatal cells. Eur. J. Neurosci. 23, 1701 1710.
28. Moreno J. A., Sullivan K. A., Carbone D. L., Hanneman W. H. Tjalkens R. B. (2008) Manganese potentiates nuclear factor-kappaB-dependent expression of nitric oxide synthase 2 in astrocytes by activating soluble guanylate cyclase and extracellular responsive kinase signaling pathways. J. Neurosci. Res. 86, 2028 2038.
29. 2+ handling in Huntington's disease striatal cells: effect of histone deacetylase inhibitors. J. Neurosci. 26, 11174 11186.
30. Ravikumar B., Vacher C., Berger Z. et al. (2004) Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat. Genet. 36, 585 595.
31. Rigon A. P., Cordova F. M., Oliveira C. S. et al. (2008) Neurotoxicity of cadmium on immature hippocampus and a neuroprotective role for p38 MAPK. Neurotoxicology 29, 727 734.
32. Ruan Q., Lesort M., MacDonald M. E. Johnson G. V. (2004) Striatal cells from mutant huntingtin knock-in mice are selectively vulnerable to mitochondrial complex II inhibitor-induced cell death through a non-apoptotic pathway. Hum. Mol. Genet. 13, 669 681.
33. Seong I. S., Ivanova E., Lee J. M. et al. (2005) HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum. Mol. Genet. 14, 2871 2880.
34. Simmons D. A., Casale M., Alcon B., Pham N., Narayan N. Lynch G. (2007) Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington's disease. Glia 55, 1074 1084.
35. Slow E. J., van Raamsdonk J., Rogers D. et al. (2003) Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 12, 1555 1567.
36. Snider B. J., Moss J. L., Revilla F. J., Lee C. S., Wheeler V. C., Macdonald M. E. Choi D. W. (2003) Neocortical neurons cultured from mice with expanded CAG repeats in the huntingtin gene: unaltered vulnerability to excitotoxins and other insults. Neuroscience 120, 617 625.
37. Thevenod F. (2009) Cadmium and cellular signaling cascades: to be or not to be? Toxicol. Appl. Pharmacol. 238, 221 239.
38. Trettel F., Rigamonti D., Hilditch-Maguire P., Wheeler V. C., Sharp A. H., Persichetti F., Cattaneo E. MacDonald M. E. (2000) Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum. Mol. Genet. 9, 2799 2809.
39. Warby S. C., Chan E. Y., Metzler M., Gan L., Singaraja R. R., Crocker S. F., Robertson H. A. Hayden M. R. (2005) Huntingtin phosphorylation on serine 421 is significantly reduced in the striatum and by polyglutamine expansion in vivo. Hum. Mol. Genet. 14, 1569 1577.
40. Ying H. S., Gottron F. J. Choi D. W. (2000) Assessment of cell viability in primary neuronal cultures. Curr. Protoc. Neurosci. 13, 7.18.8 7.18.9.
41. Zecca L., Youdim M. B., Riederer P., Connor J. R. Crichton R. R. (2004) Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. 5, 863 873.
42. Zheng W., Zhao Q., Slavkovich V., Aschner M. Graziano J. H. (1999) Alteration of iron homeostasis following chronic exposure to manganese in rats. Brain Res. 833, 125 132.